Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT) (BOX-DVT)
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto® Following an Acute Deep Vein Thrombosis (DVT)|
- Real-life medical resource use consumption based on medical examination and patient diary cards [ Time Frame: Up to 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||July 2013|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01855100
|Contact: Bayer Clinical Trials Contactfirstname.lastname@example.org|
|Many locations, Belgium|
|Study Director:||Bayer Study Director||Bayer|